Paul A. Hamlin

8.1k total citations
155 papers, 4.0k citations indexed

About

Paul A. Hamlin is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Paul A. Hamlin has authored 155 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Pathology and Forensic Medicine, 62 papers in Oncology and 61 papers in Genetics. Recurrent topics in Paul A. Hamlin's work include Lymphoma Diagnosis and Treatment (128 papers), Chronic Lymphocytic Leukemia Research (61 papers) and Viral-associated cancers and disorders (32 papers). Paul A. Hamlin is often cited by papers focused on Lymphoma Diagnosis and Treatment (128 papers), Chronic Lymphocytic Leukemia Research (61 papers) and Viral-associated cancers and disorders (32 papers). Paul A. Hamlin collaborates with scholars based in United States, France and Germany. Paul A. Hamlin's co-authors include Andrew D. Zelenetz, Craig H. Moskowitz, David J. Straus, Carol S. Portlock, Ariela Noy, Steven M. Horwitz, Owen A. O’Connor, Joachim Yahalom, Stephen D. Nimer and Tarun Kewalramani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Paul A. Hamlin

146 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul A. Hamlin United States	33	2.9k	2.0k	925	914	587	155	4.0k
Matthew J. Matasar United States	32	2.7k 0.9×	2.4k 1.2×	923 1.0×	897 1.0×	430 0.7×	190	3.9k
John Sweetenham United States	34	2.8k 1.0×	2.0k 1.0×	1.5k 1.6×	746 0.8×	785 1.3×	143	4.6k
Dok Hyun Yoon South Korea	35	2.1k 0.7×	2.4k 1.2×	572 0.6×	541 0.6×	721 1.2×	303	4.3k
Christophe Fermé France	26	3.7k 1.3×	2.4k 1.2×	1.2k 1.3×	1.3k 1.4×	404 0.7×	98	4.3k
Andrew McMillan United Kingdom	32	2.6k 0.9×	2.4k 1.2×	944 1.0×	909 1.0×	472 0.8×	117	5.5k
Hervé Ghesquières France	31	2.1k 0.7×	1.6k 0.8×	852 0.9×	877 1.0×	410 0.7×	193	3.0k
Catherine Sebban France	24	2.3k 0.8×	1.8k 0.9×	862 0.9×	575 0.6×	397 0.7×	68	3.0k
Michael Millenson United States	22	2.0k 0.7×	3.0k 1.5×	747 0.8×	619 0.7×	1.4k 2.4×	64	4.5k
Simon Rule United Kingdom	30	2.4k 0.8×	1.7k 0.8×	1.6k 1.7×	343 0.4×	519 0.9×	155	3.4k
Caterina Stelitano Italy	32	3.0k 1.1×	1.4k 0.7×	1.1k 1.2×	1.3k 1.4×	297 0.5×	114	3.8k

Countries citing papers authored by Paul A. Hamlin

Since Specialization

Citations

This map shows the geographic impact of Paul A. Hamlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Hamlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Hamlin more than expected).

Fields of papers citing papers by Paul A. Hamlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Hamlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Hamlin. The network helps show where Paul A. Hamlin may publish in the future.

Co-authorship network of co-authors of Paul A. Hamlin

This figure shows the co-authorship network connecting the top 25 collaborators of Paul A. Hamlin. A scholar is included among the top collaborators of Paul A. Hamlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul A. Hamlin. Paul A. Hamlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamlin, Paul A., Anita Kumar, Matthew J. Matasar, et al.. (2024). A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma. Leukemia & lymphoma. 65(14). 2224–2227.

Ghione, Paola, Erel Joffe, M. Lia Palomba, et al.. (2024). CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas. PubMed. 1(4). 100031–100031. 1 indexed citations

Smith, Alexandra N., Matthew J. Maurer, Julie Teruya‐Feldstein, et al.. (2024). Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood Advances. 8(9). 2172–2181. 2 indexed citations

Luttwak, Efrat, Esther Drill, Nivetha Ganesan, et al.. (2024). Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience. Blood. 144(Supplement 1). 1668–1668.

Kumar, Anita, Carla Casulo, Erel Joffe, et al.. (2022). Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Leukemia & lymphoma. 63(12). 2889–2896. 1 indexed citations

Joffe, Erel, Yan Leyfman, Esther Drill, et al.. (2021). Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Advances. 5(2). 345–351. 7 indexed citations

Imber, Brandon S., Karen Chau, Jisun Lee, et al.. (2021). Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. Blood Advances. 5(20). 4185–4197. 21 indexed citations

Kumar, Anita, Fushen Sha, Ahmed Toure, et al.. (2019). Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer Journal. 9(6). 50–50. 76 indexed citations

Borchmann, Sven, Erel Joffe, Craig H. Moskowitz, et al.. (2019). Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 133(20). 2121–2129. 26 indexed citations

10.

Evens, Andrew M., Ranjana H. Advani, Irene Helenowski, et al.. (2018). Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Journal of Clinical Oncology. 36(30). 3015–3022. 96 indexed citations

11.

Vardhana, Santosha A., Paul A. Hamlin, Joanna C. Yang, et al.. (2018). Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. Biology of Blood and Marrow Transplantation. 24(10). 2133–2138. 28 indexed citations

12.

Batlevi, Connie Lee, Caitlin M. Stewart, Paul A. Hamlin, et al.. (2018). Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 7520–7520. 8 indexed citations

13.

Schöder, Heiko, Andrew D. Zelenetz, Paul A. Hamlin, et al.. (2015). Prospective Study of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of Nuclear Medicine. 57(5). 728–734. 30 indexed citations

14.

Moskowitz, Craig H., Heiko Schöder, Julie Teruya‐Feldstein, et al.. (2010). Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. 28(11). 1896–1903. 225 indexed citations

15.

Hurria, Arti, Daneng Li, Kurt Hansen, et al.. (2009). Distress in Older Patients With Cancer. Journal of Clinical Oncology. 27(26). 4346–4351. 101 indexed citations

16.

O’Connor, Owen A., Steven M. Horwitz, Paul A. Hamlin, et al.. (2009). Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. Journal of Clinical Oncology. 27(26). 4357–4364. 131 indexed citations

17.

Noy, Ariela, Heiko Schöder, Mithat Gönen, et al.. (2009). The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Annals of Oncology. 20(3). 508–512. 107 indexed citations

18.

Gerecitano, John F., Carol S. Portlock, Craig H. Moskowitz, et al.. (2009). Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology. 146(6). 652–655. 39 indexed citations

19.

Liedtke, Michaela, Paul A. Hamlin, Craig H. Moskowitz, & Andrew D. Zelenetz. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Annals of Oncology. 17(6). 909–913. 71 indexed citations

20.

Hamlin, Paul A., Ellen Neylon, Craig H. Moskowitz, et al.. (2005). Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.. Blood. 106(11). 2678–2678. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact